Skip to main content
AAN.com
Articles
August 14, 2001

Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy [RETRACTED]

This article has been corrected.
VIEW CORRECTION
August 14, 2001 issue
57 (3) 445-449

Abstract

Background: Bone loss and hypovitaminosis D are reported in patients taking antiepileptic drugs, but little is known about changes in bone and calcium metabolism from valproic acid (VPA).
Objective: To assess the relationship of VPA to bone mass and calcium metabolism in 40 adults with epilepsy on long-term VPA monotherapy, 40 age- and sex-matched epileptic patients taking phenytoin (PHT), and 40 healthy control subjects. Bone mineral density (BMD) of the second metacarpal was determined as T- and Z-scores.
Results: BMD reduction from control values was 14% (12% in men, 16% in women) with VPA and 13% (12% in men, 15% in women) with PHT. Among patients on VPA, nine (23%) had T-scores below −2.5 SD, suggesting osteoporosis; 15 (37%) had T-scores between −1 and −2.5 SD, suggesting osteopenia. Serum concentrations of calcium were significantly higher with VPA than in PHT or control groups. Serum concentrations of bone Gla protein (a bone formation marker) and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP; a bone resorption marker) associated with either drug significantly exceeded control values. Z-scores for BMD in the VPA group correlated negatively with calcium and ICTP. High ICTP correlated positively with ionized calcium, implying that increased bone resorption caused the latter.
Conclusion: Long-term VPA monotherapy can increase bone resorption, leading to decreased BMD.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 57Number 3August 14, 2001
Pages: 445-449
PubMed: 11502911

Publication History

Received: February 5, 2001
Accepted: April 4, 2001
Published online: August 14, 2001
Published in issue: August 14, 2001

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Y. Sato, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
I. Kondo, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
S. Ishida, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
H. Motooka, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
K. Takayama, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
Y. Tomita, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
H. Maeda, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.
K. Satoh, MD
From the Departments of Internal Medicine (Dr. Sato) and Neuropsychiatry (Drs. Ishida, Motooka, Takayama, Tomita, and Maeda), Kurume University School of Medicine; and the Departments of Rehabilitation Medicine (Drs. Sato and Kondo) and Vascular Biology (Dr. Satoh), Institute of Brain Science, Hirosaki University School of Medicine, Japan.

Notes

Address correspondence and reprint requests to Dr. Yoshihiro Sato, Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Effectiveness and Adverse Drug Reaction Mechanisms Associated with Valproic Acid Use: A Cross-Sectional Prospective Study in Indonesia, Biomedical and Pharmacology Journal, 18, 1, (739-748), (2025).https://doi.org/10.13005/bpj/3124
    Crossref
  2. Antiseizure Medications and Hormones, Women with Epilepsy, (84-100), (2024).https://doi.org/10.1017/9781009006903.005
    Crossref
  3. Serum level of sclerostin and vitamin D in children with epilepsy, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 60, 1, (2024).https://doi.org/10.1186/s41983-024-00857-1
    Crossref
  4. Diş Hekimliğinde Fraktal Analiz Kullanımı: Derleme, Journal of International Dental Sciences, (2024).https://doi.org/10.21306/dishekimligi.1443780
    Crossref
  5. Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss, Signal Transduction and Targeted Therapy, 9, 1, (2024).https://doi.org/10.1038/s41392-023-01726-8
    Crossref
  6. Epilepsy and Anti-Seizure Medications: Secret Agents for Endocrine Disruption, Epilepsy Currents, 24, 2, (79-83), (2023).https://doi.org/10.1177/15357597231213248
    Crossref
  7. Assessment of bone mineral density in epileptic patients with long-term antiepileptic therapy: pilot data, V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, 57, 4, (75-89), (2023).https://doi.org/10.31363/2313-7053-2023-859
    Crossref
  8. A retrospective comparative fractal and radiomorphometric analysis of the effect of 3 generations of anti-epileptic drugs on the mandible, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 136, 2, (255-262), (2023).https://doi.org/10.1016/j.oooo.2023.04.014
    Crossref
  9. Psychopharmacology, The American Psychiatric Association Publishing Textbook of Geriatric Psychiatry, (2023).https://doi.org/10.1176/appi.books.9781615375196.ds20
    Crossref
  10. Experimental study on the effects of simvastatin in reversing the femoral metaphyseal defects induced by sodium valproate in normal and ovariectomized rats, Heliyon, 8, 9, (e10480), (2022).https://doi.org/10.1016/j.heliyon.2022.e10480
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Share article link

Share